Premium
Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma
Author(s) -
Eltabbakh Gamal H.,
Mount Sharon L.,
Beatty Barbara,
SimmonsArnold Linda,
Cooper Kumarasen
Publication year - 2006
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.20494
Subject(s) - medicine , ovarian cancer , immunohistochemistry , serous fluid , paclitaxel , clear cell carcinoma , chemotherapy , cancer research , clear cell , carcinoma , cancer , oncology , pathology
Abstract Purpose The aim of the current study is to compare clear cell ovarian carcinoma (CCOC) and papillary serous ovarian carcinoma (PSOC) with respect to their clinical features and expression of different regulators of cell cycle, apoptosis, and chemoresistance. Experimental Design Women with stage III CCOC (n = 9) and those with stage III, poorly differentiated PSOC (n = 21) seen between 1996 and 2000 and treated with cytoreductive surgery followed by paclitaxel and platinum chemotherapy were compared in their demographic features, tumor marker profile, surgical substage, results of cytoreductive surgery, thromboembolic complications, response to chemotherapy, and tumor recurrence. Tumor samples were compared in their expression of p53, Bcl 2 , Bcl x , Bax, p21, p‐glycoprotein (PGP), multi‐drug resistance‐associated protein (MRP), lung resistance protein (LRP), and glutathione S‐transferase (GST) using immunohistochemistry. Results Women with CCOC had significantly lower mean preoperative CA‐125 values, lower surgical substage, less expression of p53, and more expression of p21 than women with PSOC ( P = 0.037, 0.012, 0.008, and 0.009, respectively). Women with CCOC had less ascites, smaller amount of residual tumor, higher incidence of thromboembolism, chemoresistance, more expression of Bcl 2 , and less expression of PGP than women with PSOC ( P = 0.067, 0.078, 0.108, 0.114, 0.091, and 0.118, respectively). Conclusions Women with CCOC exhibit certain clinical and molecular differences compared to stage‐ and grade‐matched women with PSOC. Women with CCOC have a smaller tumor volume and manifest different expressions of p53, p21, and Bcl 2 than women with PSOC. Although further studies with larger number of patients are needed, our findings indicate that chemoresisatnce in CCOC is probably not p53‐dependent. J. Surg. Oncol. 2006;93:379–386. © 2006 Wiley‐Liss, Inc.